Article Archive for January 2010
On December 2, 2009 Novavax, Inc. (NASDAQ:NVAX) announced that it has received encouraging primary data from the first stage of the Phase 2 trial. The trial is being carried out on the company’s newly developed …
Nanosphere Inc. (NASDAQ:NSPH) is a pharmaceutical company that develops, manufactures and then brings into market “advanced molecular diagnostics systems” which detect “multiplexed direct genomic and ultra-sensitive protein detection”. All its products are based on the …
On December 29, 2009, AspenBio Pharma, Inc. (NASDAQ: APPY), which is a growing bio science company that develops innovative tests and drugs for the betterment of mankind, disclosed information about the Premarket Notification 510(K) that …
On June 1, 2009, Exelixis, Inc. (NASDAQ:EXEL) announced that they received favorable results from the Phase 1 trial of XL765. The trial dealt with finding the effects of increasing the dose of XL765. XL765 is …
Hypoxia Activated Prodrug (also called HAP in short) is a type of anti cancer drug that is used by patients suffering from Tumor Hypoxia. This is condition where there is a lack of oxygen in …
Cladribine Tablets is a drug for young adults, especially females, who are suffering from multiple sclerosis (MS), which is a neurological disorder that affects the nerve cells in the spinal cord and the brain. The …
On November 19, 2009, Advanced Cell Technology, Inc. (NASDAQ: ACTC.OB), which is a biotechnology company that uses cloning techniques to develop a number of life-saving drugs, disclosed that the company has sent an Investigational New …
Acurox (containing a combination of oxycodone HCL ad niacin) is a drug that – through the use of Aversion Technology – aims to alleviate moderate and severe pain, and to prevent various misuse and abuse …
On December 15, 2009, Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) disclosed some crucial information from the initial results of the second stage of the Phase 1 trial.
Stedesa (eslicarbazepine acetate) is a drug for adults who are suffering from epilepsy, which is a chronic and common neurological disorder that causes frequent seizures. This drug has been developed by Sepracor Inc. (NASDAQ:SEPR).
